Providing innovative tools to screen and monitor cognitive changes in the clinical and community settings.
As part of this partnership, Cogstate is proud to be a strategic investment of Eisai Innovation, which focuses on neurology and oncology digital solutions and diagnostics to advance human health care (hhc).
In the next decade, better solutions for screening, diagnosis, and treatment of brain disorders are imperative. Cogstate delivers innovative solutions through our technology and partnerships to support clinical evaluation and self-assessment of brain health.
Cogstate technology is leveraged by clinicians to help screen and monitor cognitive impairment related to a variety of brain disorders.
Eisai and Cogstate have developed a consumer-friendly self-assessment of brain performance. The NouKNOW™ tool couples a brain health score with lifestyle advice for maintaining brain performance.
1 in 10 people aged 65 years or older has Alzheimer’s disease.
The Cognigram system detects very subtle changes in cognition that could signify the early stages of dementia. Because neurological changes begin 20 or more years before cognitive symptoms appear, early detection of dementia is critical.
Post-surgical delirium affects up to 50% of patients, costing $164 billion per year.
In the perioperative setting, postoperative cognitive dysfunction (POCD) occurs in up to 53% of patients over 65 years of age and in patients with moderate to severe cases, decline in cognitive function can be substantial and long term.
42 million people globally suffer from concussion each year.
The Cognigram system offers unique value as a sensitive and reliable tool for baseline testing and post-injury evaluation. Sport organizations ranging from secondary education to professional and elite groups around the world depend upon its test battery for decision support in their concussion management programs.
Please fill out the form to get in touch
